MA51815A - Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp - Google Patents

Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp

Info

Publication number
MA51815A
MA51815A MA051815A MA51815A MA51815A MA 51815 A MA51815 A MA 51815A MA 051815 A MA051815 A MA 051815A MA 51815 A MA51815 A MA 51815A MA 51815 A MA51815 A MA 51815A
Authority
MA
Morocco
Prior art keywords
migraines
prevention
treatment
methods
antibodies against
Prior art date
Application number
MA051815A
Other languages
English (en)
French (fr)
Inventor
Eduardo Dunayevich
Sun Hong
Robert A Lenz
Gabriel Vargas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA51815A publication Critical patent/MA51815A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
MA051815A 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp MA51815A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
MA51815A true MA51815A (fr) 2020-12-23

Family

ID=53969433

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41932A MA41932B1 (fr) 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines
MA051815A MA51815A (fr) 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41932A MA41932B1 (fr) 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines

Country Status (30)

Country Link
US (3) US10259877B2 (sr)
EP (2) EP3653225A1 (sr)
JP (4) JP6392471B2 (sr)
KR (1) KR102464415B1 (sr)
CN (2) CN113908268A (sr)
AU (2) AU2015392215B2 (sr)
BR (1) BR112017022772A2 (sr)
CA (1) CA2984254C (sr)
CL (1) CL2017002686A1 (sr)
CY (1) CY1123211T1 (sr)
DK (1) DK3285803T3 (sr)
ES (1) ES2771925T3 (sr)
HK (1) HK1250914A1 (sr)
HR (1) HRP20200056T1 (sr)
HU (1) HUE048528T2 (sr)
IL (2) IL255114B (sr)
JO (2) JOP20200116A1 (sr)
LT (1) LT3285803T (sr)
MA (2) MA41932B1 (sr)
MX (2) MX2017013627A (sr)
PH (1) PH12017501934A1 (sr)
PL (1) PL3285803T3 (sr)
PT (1) PT3285803T (sr)
RS (1) RS59912B1 (sr)
RU (1) RU2707745C2 (sr)
SG (2) SG10202004282RA (sr)
SI (1) SI3285803T1 (sr)
TW (2) TWI728953B (sr)
WO (1) WO2016171742A1 (sr)
ZA (1) ZA201707179B (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2018160896A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
WO2019055399A1 (en) * 2017-09-12 2019-03-21 Igc Bio, Inc. ANTI-VEGF ANTIBODIES
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
CN111954678A (zh) 2018-04-02 2020-11-17 美国安进公司 厄瑞努单抗组合物及其用途
EP3817766A2 (en) * 2018-07-05 2021-05-12 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
JP2022533030A (ja) * 2019-05-02 2022-07-21 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の治療
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
US20210130445A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
US20210128724A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
EP4076422A4 (en) * 2019-12-18 2024-01-24 Curasen Therapeutics, Inc. METHODS FOR MITIGATION OF NEUROLOGICAL DISEASES AND DISORDERS
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
JPH07504802A (ja) 1992-03-17 1995-06-01 ノバルティス　アクチェンゲゼルシャフト 遺伝子操作抗体
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
WO2003027252A2 (en) 2001-09-27 2003-04-03 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE60326370D1 (de) 2002-08-12 2009-04-09 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US9072777B2 (en) 2005-06-16 2015-07-07 Takayuki Shindo Method for screening substance having proangiogenic effect
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2664854T3 (es) * 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
AU2006316642A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam tricyclic CGRP receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
CA2650932C (en) 2006-05-09 2013-01-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
EP2146715A4 (en) 2007-04-11 2011-08-31 Merck Sharp & Dohme CGRP RECEPTOR ANTAGONISTS COMPRISING TERTIARY AMIDE, SULFAMIDE, CARBAMATE AND UREA TERMINAL GROUPS
CA2683757A1 (en) 2007-04-16 2008-10-30 Merck & Co., Inc. Aryl heterocyclic cgrp receptor antagonists
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
ES2584907T3 (es) 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
JP2011523958A (ja) 2008-06-12 2011-08-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストとしての分岐状３−及び６−置換キノリン
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
WO2010033421A1 (en) 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone cgrp receptor antagonists
AU2009298752A1 (en) 2008-10-03 2010-04-08 Merck Sharp & Dohme Corp. CGRP receptor antagonists
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
RS61793B1 (sr) 2011-05-20 2021-06-30 H Lundbeck As Anti-cgrp kompozicije i njihova upotreba
NZ717704A (en) * 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
DK2709663T3 (da) * 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2017003247A (es) * 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.

Also Published As

Publication number Publication date
HUE048528T2 (hu) 2020-07-28
JP6707590B2 (ja) 2020-06-10
CN108156814A (zh) 2018-06-12
JP2018513871A (ja) 2018-05-31
KR102464415B1 (ko) 2022-11-04
US20230020514A1 (en) 2023-01-19
RU2707745C2 (ru) 2019-11-29
JP6392471B2 (ja) 2018-09-19
SG11201708607WA (en) 2017-11-29
PT3285803T (pt) 2020-02-18
MA41932B1 (fr) 2020-04-30
MX2017013627A (es) 2018-07-06
JP2020143115A (ja) 2020-09-10
IL291153A (en) 2022-05-01
KR20180002711A (ko) 2018-01-08
PH12017501934A1 (en) 2018-03-19
LT3285803T (lt) 2020-02-10
EP3653225A1 (en) 2020-05-20
IL255114A0 (en) 2017-12-31
IL291153B2 (en) 2023-06-01
ES2771925T3 (es) 2020-07-07
RU2017140789A (ru) 2019-05-24
AU2015392215A1 (en) 2017-11-09
US20190256607A1 (en) 2019-08-22
AU2022204866A1 (en) 2022-08-18
DK3285803T3 (da) 2020-02-17
JOP20200116A1 (ar) 2017-06-16
AU2015392215B2 (en) 2022-04-07
SI3285803T1 (sl) 2020-02-28
EP3285803A1 (en) 2018-02-28
RU2017140789A3 (sr) 2019-05-24
BR112017022772A2 (pt) 2018-07-31
CN113908268A (zh) 2022-01-11
US11466090B2 (en) 2022-10-11
CL2017002686A1 (es) 2018-05-11
HRP20200056T1 (hr) 2020-04-03
TW201637667A (zh) 2016-11-01
TWI728953B (zh) 2021-06-01
CA2984254A1 (en) 2016-10-27
TW202130369A (zh) 2021-08-16
IL255114B (en) 2022-04-01
ZA201707179B (en) 2020-01-29
PL3285803T3 (pl) 2020-06-01
MX2021013327A (es) 2021-11-17
CY1123211T1 (el) 2021-12-31
RS59912B1 (sr) 2020-03-31
JP2022126724A (ja) 2022-08-30
US20160311913A1 (en) 2016-10-27
JP7544766B2 (ja) 2024-09-03
SG10202004282RA (en) 2020-06-29
JO3559B1 (ar) 2020-07-05
CN108156814B (zh) 2021-07-09
US10259877B2 (en) 2019-04-16
TWI799849B (zh) 2023-04-21
JP2019001800A (ja) 2019-01-10
WO2016171742A1 (en) 2016-10-27
EP3285803B1 (en) 2019-12-18
CA2984254C (en) 2019-09-24
HK1250914A1 (zh) 2019-01-18

Similar Documents

Publication Publication Date Title
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
CL2018000732A1 (es) Variantes optimizadas de anticuerpos anti-vegf.
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55694A (fr) Méthodes de conditionnement de patients pour la thérapie cellulaire t
MA42366A (fr) Dispositif pour traiter, prévenir ou réduire la myopie, ou le risque de celle-ci
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
MA41449A (fr) Polythérapies pour le traitement de cancers
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
PH12016502167A1 (en) Hdl theraphy markers
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
BR112016027906A2 (pt) operação à prova de falhas de dispositivo montável no olho
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
MA42999A (fr) Polythérapie pour le traitement de malignités
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
MA45552A (fr) Compositions destinées au traitement de l'amylose
FI20155329A (fi) Raakakuparin kuumaraffinointi
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
FR3022234B1 (fr) Procede de preparation de nanofils de silicium.
MA46734A (fr) Détection améliorée de changements de fluide
MA41202A (fr) Copolymères polydiallymine réticulé pour le traitement du diabète de type 2